How does lipid lowering prevent coronary events? New insights from human imaging trials

被引：37
|
作者：
Libby, Peter [1 ]
机构：
[1] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiovasc Med,Dept Med, Boston, MA 02115 USA
来源：
EUROPEAN HEART JOURNAL | 2015年 / 36卷 / 08期
关键词：
IN-VIVO; THERAPY;
D O I：
10.1093/eurheartj/ehu510
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：472 / 474
页数：3
相关论文
共 50 条
  • [1] Intensive lipid lowering agents and coronary atherosclerosis: Insights from intravascular imaging
    Di Giovanni, Giuseppe
    Nicholls, Stephen J.
    AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2022, 11
  • [2] LIPID-LOWERING AND PLAQUE REGRESSION - NEW INSIGHTS INTO PREVENTION OF PLAQUE DISRUPTION AND CLINICAL EVENTS IN CORONARY-DISEASE
    BROWN, BG
    ZHAO, XQ
    SACCO, DE
    ALBERS, JJ
    CIRCULATION, 1993, 87 (06) : 1781 - 1791
  • [3] THE DIFFERENT LIPID LOWERING TARGET BY STATINS FOR JAPANESE TO PREVENT CARDIOVASCULAR EVENTS AFTER PERCUTANEOUS CORONARY INTERVENTIONS
    Sakamoto, T.
    Ogawa, H.
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [4] How does the "NICE" approach to lipid lowering differ from that of the US?
    Cooper, A.
    O'Flynn, N.
    JOURNAL OF FAMILY PRACTICE, 2008, 57 (09): : 574 - 575
  • [5] The Goal of Achieving Atherosclerotic Plaque Regression with Lipid-Lowering Therapy: Insights from IVUS Trials
    Daida, Hiroyuki
    Dohi, Tomotaka
    Fukushima, Yoshifumi
    Ohmura, Hirotoshi
    Miyauchi, Katsumi
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2019, 26 (07) : 592 - 600
  • [6] Lipid Lowering Therapy to Modify Plaque Microstructures: Insights from Optical Coherence Tomography Imaging
    Kataoka, Yu
    Andrews, Jordan
    Puri, Rishi
    Psaltis, Peter
    Nicholls, Stephen J.
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2017, 24 (04) : 360 - 372
  • [7] Does management of lipid lowering differ between specialists and primary care: Insights from GOAL Canada
    Langer, Anatoly
    Tan, Mary
    Goodman, Shaun G.
    Gregoire, Jean
    Lin, Peter J.
    Mancini, G. B. John
    Stone, James A.
    Leiter, Lawrence A.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2021, 75 (04)
  • [8] Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy
    Isles, CG
    Paterson, JR
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2000, 93 (09) : 567 - 574
  • [9] Lipid-lowering trials in the primary and secondary prevention of coronary heart disease: New evidence, implications and outstanding issues
    Watts, GF
    Burke, V
    CURRENT OPINION IN LIPIDOLOGY, 1996, 7 (06) : 341 - 355
  • [10] Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?
    Tenenbaum, Alexander
    Boyko, Valentina
    Fisman, Enrique Z.
    Goldenberg, Ilan
    Adler, Yehuda
    Feinberg, Micha S.
    Motro, Michael
    Tanne, David
    Shemesh, Joseph
    Schwammenthal, Ehud
    Behar, Solomon
    CARDIOVASCULAR DIABETOLOGY, 2008, 7 (1)
12345